{ "run": { "id": "cmnr12il302d0p6589gihpzyg", "region": "US", "assetId": "cmnr12ik802cwp658h14wr97a", "ticker": "BDX", "snapshotId": "cmnr12ikw02cyp6581bmhs4ct", "promptTemplateId": "cmnqt07si0005lm3jzpxuu1ux", "createdAt": "2026-04-09T05:19:47.605Z", "promptTemplate": { "id": "cmnqt07si0005lm3jzpxuu1ux", "name": "Oficial 08.apr.2026", "version": 1 }, "snapshot": { "id": "cmnr12ikw02cyp6581bmhs4ct", "assetId": "cmnr12ik802cwp658h14wr97a", "asOf": "2026-04-08T20:00:03.000Z", "snapshot": { "asOf": "2026-04-08T20:00:03.000Z", "quote": { "asOf": "2026-04-08T20:00:03.000Z", "open": null, "price": 157.09, "dayLow": 156.16, "volume": 2186904, "dayHigh": 159.23, "currency": "USD", "prevClose": 154.96, "week52Low": 127.586, "week52High": 187.35 }, "fundamentals": { "pe": 31.8394854202401, "beta": 0.470656136140803, "epsTTM": 5.83, "fcfTTM": 792000000, "growth": { "epsYoy": -0.008503401360544187, "revenueYoy": -0.7595238095238095 }, "sector": "Surgical & Medical Instruments & Apparatus", "margins": { "net": 0.0510603493602851, "gross": 0.4426593445113046, "operating": 0.08669743529824152 }, "website": "http://bd.com", "industry": "Medical equipment", "pegRatio": -37.4432348542026, "ebitdaTTM": 5352000000, "forwardPe": 12.5083692722372, "marketCap": 65472902857, "totalCash": 740000000, "totalDebt": 19539000000, "debtEquity": 0.755454903505317, "quickRatio": 0.370733934482365, "revenueTTM": 17117000000, "companyName": "BECTON DICKINSON & CO", "priceToBook": 1.1357617178933, "currentRatio": 1.048852870676863, "dividendYield": 0.0223993402055623, "returnOnAssets": 0.01593698145548039, "returnOnEquity": 0.0660890114218196, "analystOpinions": null, "businessSummary": "Becton, Dickinson and Company (BD; also Becton Dickinson or Becton) is an American multinational medical technology company that manufactures and sells medical devices, instrument systems, and reagents. BD also provides consulting and analytics services in certain areas.", "enterpriseValue": 71934429881.6, "analystTargetLow": null, "analystTargetHigh": null, "analystTargetMean": null, "fullTimeEmployees": 72000, "sharesOutstanding": 284741809, "enterpriseToEbitda": 13.4406632813154, "analystTargetMedian": null, "enterpriseToRevenue": 4.202513868177835, "operatingCashflowTTM": 657000000, "analystRecommendationKey": null } }, "createdAt": "2026-04-09T05:19:47.600Z" }, "results": [ { "id": "cmnr12il602d2p658193e06he", "runId": "cmnr12il302d0p6589gihpzyg", "modelId": "anthropic", "status": "SUCCESS", "rawOutput": "{\"model\":\"ai-equity-research-v1\",\"as_of\":\"2026-04-08T20:00:03.000Z\",\"ticker\":\"BDX\",\"currency\":\"USD\",\"current_price\":157.09,\"target_price_6m\":167.5,\"target_price_12m\":178.0,\"recommendation\":\"BUY\",\"confidence\":0.58,\"thesis_bullets\":[\"Forward PE of 12.5x implies significant earnings recovery ahead\",\"Planned corporate separation may unlock hidden segment value\",\"High debt load ($19.5B) constrains near-term financial flexibility\",\"Gross margins ~44% suggest pricing power but operating margins compressed\",\"Defensive medtech positioning with 0.47 beta supports downside protection\"],\"key_drivers\":[{\"driver\":\"Planned separation into two focused companies\",\"impact\":\"HIGH\",\"direction\":\"POS\"},{\"driver\":\"Forward EPS ~$12.56 implies margin normalization\",\"impact\":\"HIGH\",\"direction\":\"POS\"},{\"driver\":\"Total debt of $19.5B vs $740M cash\",\"impact\":\"HIGH\",\"direction\":\"NEG\"},{\"driver\":\"Negative TTM revenue growth (-0.76% YoY)\",\"impact\":\"MED\",\"direction\":\"NEG\"},{\"driver\":\"Dividend yield ~2.2% provides income floor\",\"impact\":\"LOW\",\"direction\":\"POS\"},{\"driver\":\"Operating margin at 8.7% well below medtech peer average\",\"impact\":\"MED\",\"direction\":\"NEG\"},{\"driver\":\"EV/EBITDA of 13.4x reasonable relative to medtech peers\",\"impact\":\"MED\",\"direction\":\"POS\"},{\"driver\":\"Edwards Critical Care integration synergies\",\"impact\":\"MED\",\"direction\":\"POS\"},{\"driver\":\"Quick ratio of 0.37 signals tight near-term liquidity\",\"impact\":\"MED\",\"direction\":\"NEG\"}],\"risks\":[\"Separation execution risk could delay value realization\",\"Debt servicing burden rises if rates stay elevated\",\"Organic revenue growth stalls amid competitive pressure\",\"Margin recovery fails to materialize post-separation\",\"Regulatory or reimbursement headwinds in key product lines\"],\"assumptions\":{\"revenue_cagr_3y\":0.04,\"ebit_margin_target\":0.18,\"wacc\":0.085,\"terminal_multiple\":15.0},\"scenarios\":{\"bear\":{\"target_price\":135.0,\"prob\":0.2,\"notes\":\"Separation delayed or value-destructive; margins stay compressed and debt weighs.\"},\"base\":{\"target_price\":178.0,\"prob\":0.55,\"notes\":\"Orderly separation, moderate margin recovery toward 18%, forward PE re-rates to ~14x.\"},\"bull\":{\"target_price\":210.0,\"prob\":0.25,\"notes\":\"Smooth separation unlocks re-rating; strong synergy realization and margin expansion.\"}},\"method_notes\":\"Blended valuation using forward PE (snapshot fwd PE 12.5x, target 14-16x on est. ~$12.56 fwd EPS) and EV/EBITDA cross-check (13.4x current vs 14-15x target). Expected 12M return ~13.3% supports BUY. Confidence moderate due to separation uncertainty, high leverage, and compressed margins. Probability-weighted scenario value ~$176, consistent with base. Sell-side targets referenced only as context, not as model inputs. Not investment advice.\"}", "parsedJson": { "as_of": "2026-04-08T20:00:03.000Z", "model": "ai-equity-research-v1", "risks": [ "Separation execution risk could delay value realization", "Debt servicing burden rises if rates stay elevated", "Organic revenue growth stalls amid competitive pressure", "Margin recovery fails to materialize post-separation", "Regulatory or reimbursement headwinds in key product lines" ], "ticker": "BDX", "currency": "USD", "scenarios": { "base": { "prob": 0.55, "notes": "Orderly separation, moderate margin recovery toward 18%, forward PE re-rates to ~14x.", "target_price": 178 }, "bear": { "prob": 0.2, "notes": "Separation delayed or value-destructive; margins stay compressed and debt weighs.", "target_price": 135 }, "bull": { "prob": 0.25, "notes": "Smooth separation unlocks re-rating; strong synergy realization and margin expansion.", "target_price": 210 } }, "confidence": 0.58, "assumptions": { "wacc": 0.085, "revenue_cagr_3y": 0.04, "terminal_multiple": 15, "ebit_margin_target": 0.18 }, "key_drivers": [ { "driver": "Planned separation into two focused companies", "impact": "HIGH", "direction": "POS" }, { "driver": "Forward EPS ~$12.56 implies margin normalization", "impact": "HIGH", "direction": "POS" }, { "driver": "Total debt of $19.5B vs $740M cash", "impact": "HIGH", "direction": "NEG" }, { "driver": "Negative TTM revenue growth (-0.76% YoY)", "impact": "MED", "direction": "NEG" }, { "driver": "Dividend yield ~2.2% provides income floor", "impact": "LOW", "direction": "POS" }, { "driver": "Operating margin at 8.7% well below medtech peer average", "impact": "MED", "direction": "NEG" }, { "driver": "EV/EBITDA of 13.4x reasonable relative to medtech peers", "impact": "MED", "direction": "POS" }, { "driver": "Edwards Critical Care integration synergies", "impact": "MED", "direction": "POS" }, { "driver": "Quick ratio of 0.37 signals tight near-term liquidity", "impact": "MED", "direction": "NEG" } ], "method_notes": "Blended valuation using forward PE (snapshot fwd PE 12.5x, target 14-16x on est. ~$12.56 fwd EPS) and EV/EBITDA cross-check (13.4x current vs 14-15x target). Expected 12M return ~13.3% supports BUY. Confidence moderate due to separation uncertainty, high leverage, and compressed margins. Probability-weighted scenario value ~$176, consistent with base. Sell-side targets referenced only as context, not as model inputs. Not investment advice.", "current_price": 157.09, "recommendation": "BUY", "thesis_bullets": [ "Forward PE of 12.5x implies significant earnings recovery ahead", "Planned corporate separation may unlock hidden segment value", "High debt load ($19.5B) constrains near-term financial flexibility", "Gross margins ~44% suggest pricing power but operating margins compressed", "Defensive medtech positioning with 0.47 beta supports downside protection" ], "target_price_6m": 167.5, "target_price_12m": 178 }, "errorsJson": { "attempts": [], "providerMeta": { "provider": "anthropic", "webSearch": { "enabled": false, "maxToolCalls": 2, "disabledReason": null }, "pauseTurns": 0, "stopReason": "end_turn" }, "sanityIssues": [] }, "latencyMs": 44057, "createdAt": "2026-04-09T05:19:47.605Z", "usage": { "inputTokens": 3580, "outputTokens": 1935, "costUsd": 0.066275 } }, { "id": "cmnr12il602d5p6588q96ogm0", "runId": "cmnr12il302d0p6589gihpzyg", "modelId": "deepseek.reasoner", "status": "SUCCESS", "rawOutput": "{\n \"model\": \"SeniorAnalystAI\",\n \"as_of\": \"2026-04-08T20:00:03.000Z\",\n \"ticker\": \"BDX\",\n \"currency\": \"USD\",\n \"current_price\": 157.09,\n \"target_price_6m\": 160,\n \"target_price_12m\": 165,\n \"recommendation\": \"HOLD\",\n \"confidence\": 0.6,\n \"thesis_bullets\": [\n \"BDX has a strong position in stable medical device markets.\",\n \"Recent revenue decline may be temporary with recovery expected.\",\n \"Margin improvement initiatives could boost profitability.\",\n \"High debt and low liquidity pose financial risks.\",\n \"Valuation is reasonable with forward P/E of 12.5.\"\n ],\n \"key_drivers\": [\n { \"driver\": \"Revenue growth recovery\", \"impact\": \"HIGH\", \"direction\": \"POS\" },\n { \"driver\": \"EBIT margin expansion\", \"impact\": \"MED\", \"direction\": \"POS\" },\n { \"driver\": \"Debt reduction efforts\", \"impact\": \"MED\", \"direction\": \"POS\" },\n { \"driver\": \"Innovation in medical technology\", \"impact\": \"HIGH\", \"direction\": \"POS\" },\n { \"driver\": \"Regulatory environment\", \"impact\": \"MED\", \"direction\": \"NEG\" },\n { \"driver\": \"Healthcare spending trends\", \"impact\": \"MED\", \"direction\": \"POS\" },\n { \"driver\": \"Competitive intensity\", \"impact\": \"HIGH\", \"direction\": \"NEG\" },\n { \"driver\": \"Economic sensitivity\", \"impact\": \"LOW\", \"direction\": \"NEG\" }\n ],\n \"risks\": [\n \"Regulatory hurdles for new products\",\n \"Pricing pressure from payers\",\n \"Supply chain vulnerabilities\",\n \"High leverage ratio\",\n \"Slow adoption of innovations\"\n ],\n \"assumptions\": {\n \"revenue_cagr_3y\": 0.02,\n \"ebit_margin_target\": 0.10,\n \"wacc\": 0.075,\n \"terminal_multiple\": 13.0\n },\n \"scenarios\": {\n \"bear\": { \"target_price\": 140, \"prob\": 0.15, \"notes\": \"Continued revenue decline and margin compression.\" },\n \"base\": { \"target_price\": 165, \"prob\": 0.70, \"notes\": \"Modest recovery in growth and margins.\" },\n \"bull\": { \"target_price\": 190, \"prob\": 0.15, \"notes\": \"Strong innovation adoption and cost savings.\" }\n },\n \"method_notes\": \"Valuation based on DCF with 2% revenue CAGR and 10% EBIT margin. 12M target implies 5% upside, within HOLD range. Not investment advice.\"\n}", "parsedJson": { "as_of": "2026-04-08T20:00:03.000Z", "model": "SeniorAnalystAI", "risks": [ "Regulatory hurdles for new products", "Pricing pressure from payers", "Supply chain vulnerabilities", "High leverage ratio", "Slow adoption of innovations" ], "ticker": "BDX", "currency": "USD", "scenarios": { "base": { "prob": 0.7, "notes": "Modest recovery in growth and margins.", "target_price": 165 }, "bear": { "prob": 0.15, "notes": "Continued revenue decline and margin compression.", "target_price": 140 }, "bull": { "prob": 0.15, "notes": "Strong innovation adoption and cost savings.", "target_price": 190 } }, "confidence": 0.6, "assumptions": { "wacc": 0.075, "revenue_cagr_3y": 0.02, "terminal_multiple": 13, "ebit_margin_target": 0.1 }, "key_drivers": [ { "driver": "Revenue growth recovery", "impact": "HIGH", "direction": "POS" }, { "driver": "EBIT margin expansion", "impact": "MED", "direction": "POS" }, { "driver": "Debt reduction efforts", "impact": "MED", "direction": "POS" }, { "driver": "Innovation in medical technology", "impact": "HIGH", "direction": "POS" }, { "driver": "Regulatory environment", "impact": "MED", "direction": "NEG" }, { "driver": "Healthcare spending trends", "impact": "MED", "direction": "POS" }, { "driver": "Competitive intensity", "impact": "HIGH", "direction": "NEG" }, { "driver": "Economic sensitivity", "impact": "LOW", "direction": "NEG" } ], "method_notes": "Valuation based on DCF with 2% revenue CAGR and 10% EBIT margin. 12M target implies 5% upside, within HOLD range. Not investment advice.", "current_price": 157.09, "recommendation": "HOLD", "thesis_bullets": [ "BDX has a strong position in stable medical device markets.", "Recent revenue decline may be temporary with recovery expected.", "Margin improvement initiatives could boost profitability.", "High debt and low liquidity pose financial risks.", "Valuation is reasonable with forward P/E of 12.5." ], "target_price_6m": 160, "target_price_12m": 165 }, "errorsJson": { "attempts": [], "providerMeta": { "endpoint": "https://api.deepseek.com/v1/chat/completions", "provider": "deepseek", "webSearch": { "enabled": false, "supported": false }, "responseFormat": "json_object" }, "sanityIssues": [] }, "latencyMs": 350, "createdAt": "2026-04-09T05:19:47.605Z", "usage": { "inputTokens": 2093, "outputTokens": 3771, "costUsd": 0.00217 } }, { "id": "cmnr12il602d3p658ugb2nqkl", "runId": "cmnr12il302d0p6589gihpzyg", "modelId": "gemini.3-pro", "status": "SUCCESS", "rawOutput": "{\n \"model\": \"EquityResearch_BDX_Base\",\n \"as_of\": \"2026-04-08T20:00:03.000Z\",\n \"ticker\": \"BDX\",\n \"currency\": \"USD\",\n \"current_price\": 157.09,\n \"target_price_6m\": 170.0,\n \"target_price_12m\": 185.0,\n \"recommendation\": \"BUY\",\n \"confidence\": 0.7,\n \"thesis_bullets\": [\n \"Defensive medical tech profile with low 0.47 beta and steady recurring revenue streams.\",\n \"Forward P/E of 12.5x presents an attractive valuation discount versus historical medtech averages.\",\n \"Alaris infusion pump regulatory clearance unlocks a significant multi-year replacement cycle and revenue tailwind.\",\n \"Elevated debt load of $19.5B requires disciplined capital allocation and limits near-term M&A.\",\n \"Margin expansion expected through operational efficiencies and easing of post-pandemic supply chain costs.\"\n ],\n \"key_drivers\": [\n {\n \"driver\": \"Alaris pump upgrade cycle\",\n \"impact\": \"HIGH\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"Hospital capital expenditure trends\",\n \"impact\": \"MED\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"Debt deleveraging progress\",\n \"impact\": \"MED\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"Raw material and freight costs\",\n \"impact\": \"MED\",\n \"direction\": \"NEG\"\n },\n {\n \"driver\": \"Base business volume recovery\",\n \"impact\": \"HIGH\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"Regulatory compliance costs\",\n \"impact\": \"LOW\",\n \"direction\": \"NEG\"\n }\n ],\n \"risks\": [\n \"Renewed FDA regulatory hurdles, warning letters, or product recalls.\",\n \"Prolonged hospital capex constraints delaying critical equipment upgrades.\",\n \"High interest burden from $19.5B debt load restricting capital flexibility.\",\n \"Foreign exchange volatility impacting international revenue conversion.\"\n ],\n \"assumptions\": {\n \"revenue_cagr_3y\": 0.045,\n \"ebit_margin_target\": 0.18,\n \"wacc\": 0.075,\n \"terminal_multiple\": 15.0\n },\n \"scenarios\": {\n \"bear\": {\n \"target_price\": 135.0,\n \"prob\": 0.2,\n \"notes\": \"Hospital capex freezes and renewed supply chain issues compress margins and delay Alaris rollout.\"\n },\n \"base\": {\n \"target_price\": 185.0,\n \"prob\": 0.6,\n \"notes\": \"Steady execution on Alaris upgrades and gradual margin expansion drive multiple re-rating to 15x forward EPS.\"\n },\n \"bull\": {\n \"target_price\": 210.0,\n \"prob\": 0.2,\n \"notes\": \"Accelerated deleveraging and robust base business growth push valuation multiples closer to historical 18x averages.\"\n }\n },\n \"method_notes\": \"Valuation based on 15x forward P/E applied to implied forward EPS, supported by DCF. Snapshot revenue YoY anomaly noted; assumed normalized 4.5% forward growth. Recommendation is BUY due to ~17.7% upside. Not investment advice.\"\n}", "parsedJson": { "as_of": "2026-04-08T20:00:03.000Z", "model": "EquityResearch_BDX_Base", "risks": [ "Renewed FDA regulatory hurdles, warning letters, or product recalls.", "Prolonged hospital capex constraints delaying critical equipment upgrades.", "High interest burden from $19.5B debt load restricting capital flexibility.", "Foreign exchange volatility impacting international revenue conversion." ], "ticker": "BDX", "currency": "USD", "scenarios": { "base": { "prob": 0.6, "notes": "Steady execution on Alaris upgrades and gradual margin expansion drive multiple re-rating to 15x forward EPS.", "target_price": 185 }, "bear": { "prob": 0.2, "notes": "Hospital capex freezes and renewed supply chain issues compress margins and delay Alaris rollout.", "target_price": 135 }, "bull": { "prob": 0.2, "notes": "Accelerated deleveraging and robust base business growth push valuation multiples closer to historical 18x averages.", "target_price": 210 } }, "confidence": 0.7, "assumptions": { "wacc": 0.075, "revenue_cagr_3y": 0.045, "terminal_multiple": 15, "ebit_margin_target": 0.18 }, "key_drivers": [ { "driver": "Alaris pump upgrade cycle", "impact": "HIGH", "direction": "POS" }, { "driver": "Hospital capital expenditure trends", "impact": "MED", "direction": "POS" }, { "driver": "Debt deleveraging progress", "impact": "MED", "direction": "POS" }, { "driver": "Raw material and freight costs", "impact": "MED", "direction": "NEG" }, { "driver": "Base business volume recovery", "impact": "HIGH", "direction": "POS" }, { "driver": "Regulatory compliance costs", "impact": "LOW", "direction": "NEG" } ], "method_notes": "Valuation based on 15x forward P/E applied to implied forward EPS, supported by DCF. Snapshot revenue YoY anomaly noted; assumed normalized 4.5% forward growth. Recommendation is BUY due to ~17.7% upside. Not investment advice.", "current_price": 157.09, "recommendation": "BUY", "thesis_bullets": [ "Defensive medical tech profile with low 0.47 beta and steady recurring revenue streams.", "Forward P/E of 12.5x presents an attractive valuation discount versus historical medtech averages.", "Alaris infusion pump regulatory clearance unlocks a significant multi-year replacement cycle and revenue tailwind.", "Elevated debt load of $19.5B requires disciplined capital allocation and limits near-term M&A.", "Margin expansion expected through operational efficiencies and easing of post-pandemic supply chain costs." ], "target_price_6m": 170, "target_price_12m": 185 }, "errorsJson": { "attempts": [], "providerMeta": { "model": "gemini-3-pro-preview", "provider": "gemini", "webSearch": { "used": false, "allowed": false, "enabled": false, "requested": false, "disabledReason": null } }, "sanityIssues": [] }, "latencyMs": 26651, "createdAt": "2026-04-09T05:19:47.605Z", "usage": { "inputTokens": 2456, "outputTokens": 866, "costUsd": 0.015304 } }, { "id": "cmnr12il602d1p6589ndo1v6s", "runId": "cmnr12il302d0p6589gihpzyg", "modelId": "openai.gpt-5.4", "status": "SUCCESS", "rawOutput": "{\"model\":\"AI Model Recommendation v2\",\"as_of\":\"2026-04-08T20:00:03.000Z\",\"ticker\":\"BDX\",\"currency\":\"USD\",\"current_price\":157.09,\"target_price_6m\":164,\"target_price_12m\":170,\"recommendation\":\"BUY\",\"confidence\":0.62,\"thesis_bullets\":[\"Forward P/E implies earnings recovery not fully priced.\",\"Recurring consumables and installed base support resilient revenue.\",\"Margins have room to normalize from depressed snapshot levels.\",\"High debt and weak liquidity limit multiple expansion.\",\"Mixed near-term fundamentals argue for only moderate upside.\"],\"key_drivers\":[{\"driver\":\"Margin normalization after restructuring\",\"impact\":\"HIGH\",\"direction\":\"POS\"},{\"driver\":\"Consumables recurring revenue mix\",\"impact\":\"HIGH\",\"direction\":\"POS\"},{\"driver\":\"Forward EPS recovery\",\"impact\":\"HIGH\",\"direction\":\"POS\"},{\"driver\":\"Debt paydown and lower interest burden\",\"impact\":\"MED\",\"direction\":\"POS\"},{\"driver\":\"Hospital capital spending caution\",\"impact\":\"MED\",\"direction\":\"NEG\"},{\"driver\":\"Regulatory or product quality issues\",\"impact\":\"HIGH\",\"direction\":\"NEG\"},{\"driver\":\"FX and emerging-market volatility\",\"impact\":\"LOW\",\"direction\":\"NEG\"}],\"risks\":[\"Leverage constrains flexibility.\",\"Procedure softness delays recovery.\",\"Integration or restructuring costs persist.\",\"Regulatory, recall, or litigation events.\"],\"assumptions\":{\"revenue_cagr_3y\":0.04,\"ebit_margin_target\":0.15,\"wacc\":0.08,\"terminal_multiple\":14},\"scenarios\":{\"bear\":{\"target_price\":140,\"prob\":0.25,\"notes\":\"Margins stay muted and deleveraging is slower than expected.\"},\"base\":{\"target_price\":170,\"prob\":0.5,\"notes\":\"Modest growth and partial margin recovery support fair-value rerating.\"},\"bull\":{\"target_price\":190,\"prob\":0.25,\"notes\":\"Execution improves, margins normalize faster, and cash conversion rebounds.\"}},\"method_notes\":\"Snapshot quote/fundamentals used as authoritative. Valuation triangulates normalized earnings and EV/EBIT-style multiples versus depressed margins; recommendation reflects ~8% 12M upside with medium uncertainty. Snapshot growth fields appear noisy, so weighted less. not investment advice\"}", "parsedJson": { "as_of": "2026-04-08T20:00:03.000Z", "model": "AI Model Recommendation v2", "risks": [ "Leverage constrains flexibility.", "Procedure softness delays recovery.", "Integration or restructuring costs persist.", "Regulatory, recall, or litigation events." ], "ticker": "BDX", "currency": "USD", "scenarios": { "base": { "prob": 0.5, "notes": "Modest growth and partial margin recovery support fair-value rerating.", "target_price": 170 }, "bear": { "prob": 0.25, "notes": "Margins stay muted and deleveraging is slower than expected.", "target_price": 140 }, "bull": { "prob": 0.25, "notes": "Execution improves, margins normalize faster, and cash conversion rebounds.", "target_price": 190 } }, "confidence": 0.62, "assumptions": { "wacc": 0.08, "revenue_cagr_3y": 0.04, "terminal_multiple": 14, "ebit_margin_target": 0.15 }, "key_drivers": [ { "driver": "Margin normalization after restructuring", "impact": "HIGH", "direction": "POS" }, { "driver": "Consumables recurring revenue mix", "impact": "HIGH", "direction": "POS" }, { "driver": "Forward EPS recovery", "impact": "HIGH", "direction": "POS" }, { "driver": "Debt paydown and lower interest burden", "impact": "MED", "direction": "POS" }, { "driver": "Hospital capital spending caution", "impact": "MED", "direction": "NEG" }, { "driver": "Regulatory or product quality issues", "impact": "HIGH", "direction": "NEG" }, { "driver": "FX and emerging-market volatility", "impact": "LOW", "direction": "NEG" } ], "method_notes": "Snapshot quote/fundamentals used as authoritative. Valuation triangulates normalized earnings and EV/EBIT-style multiples versus depressed margins; recommendation reflects ~8% 12M upside with medium uncertainty. Snapshot growth fields appear noisy, so weighted less. not investment advice", "current_price": 157.09, "recommendation": "BUY", "thesis_bullets": [ "Forward P/E implies earnings recovery not fully priced.", "Recurring consumables and installed base support resilient revenue.", "Margins have room to normalize from depressed snapshot levels.", "High debt and weak liquidity limit multiple expansion.", "Mixed near-term fundamentals argue for only moderate upside." ], "target_price_6m": 164, "target_price_12m": 170 }, "errorsJson": { "attempts": [], "providerMeta": { "provider": "openai", "webSearch": { "used": false, "enabled": false, "sources": [], "maxToolCalls": 2 }, "responseId": "resp_037df5c90934ceb00069d756721f788195a37cb378c048195e", "reasoningEffort": "medium", "structuredOutputs": { "used": true, "requested": true, "disabledReason": null } }, "sanityIssues": [] }, "latencyMs": 26833, "createdAt": "2026-04-09T05:19:47.605Z", "usage": { "inputTokens": 2367, "outputTokens": 1506, "costUsd": 0.025226 } }, { "id": "cmnr12il602d4p658sxga03a3", "runId": "cmnr12il302d0p6589gihpzyg", "modelId": "xai.grok-4.20-reasoning", "status": "SUCCESS", "rawOutput": "{\n \"model\": \"AI Equity Research Model\",\n \"as_of\": \"2026-04-08T20:00:03.000Z\",\n \"ticker\": \"BDX\",\n \"currency\": \"USD\",\n \"current_price\": 157.09,\n \"target_price_6m\": 165,\n \"target_price_12m\": 185,\n \"recommendation\": \"BUY\",\n \"confidence\": 0.62,\n \"thesis_bullets\": [\n \"Leading medtech portfolio anchors resilient healthcare demand.\",\n \"Forward P/E of 12.5x signals compelling valuation entry.\",\n \"Innovation in key segments to drive mid-single digit growth.\",\n \"High debt burden elevates financial risk and interest costs.\",\n \"Recent negative revenue trends reflect cyclical hospital pressures.\"\n ],\n \"key_drivers\": [\n {\n \"driver\": \"Innovation and new product launches\",\n \"impact\": \"HIGH\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"Recovery in hospital capital expenditures\",\n \"impact\": \"HIGH\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"EBIT margin expansion initiatives\",\n \"impact\": \"MED\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"Debt reduction and deleveraging\",\n \"impact\": \"MED\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"Regulatory approvals and compliance\",\n \"impact\": \"MED\",\n \"direction\": \"NEG\"\n },\n {\n \"driver\": \"Intense industry competition\",\n \"impact\": \"MED\",\n \"direction\": \"NEG\"\n },\n {\n \"driver\": \"Global economic and healthcare spending\",\n \"impact\": \"HIGH\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"Supply chain cost inflation\",\n \"impact\": \"LOW\",\n \"direction\": \"NEG\"\n }\n ],\n \"risks\": [\n \"Sustained weakness in hospital spending\",\n \"Product liability and litigation risks\",\n \"Integration challenges from acquisitions\",\n \"Currency fluctuations in international markets\",\n \"Failure to meet innovation pipeline milestones\"\n ],\n \"assumptions\": {\n \"revenue_cagr_3y\": 0.05,\n \"ebit_margin_target\": 0.15,\n \"wacc\": 0.075,\n \"terminal_multiple\": 14\n },\n \"scenarios\": {\n \"bear\": {\n \"target_price\": 140,\n \"prob\": 0.3,\n \"notes\": \"Continued revenue weakness and no margin improvement.\"\n },\n \"base\": {\n \"target_price\": 185,\n \"prob\": 0.5,\n \"notes\": \"Gradual recovery in growth and operating performance.\"\n },\n \"bull\": {\n \"target_price\": 225,\n \"prob\": 0.2,\n \"notes\": \"Accelerated growth from innovation and margin gains.\"\n }\n },\n \"method_notes\": \"DCF valuation anchored on 5% 3Y revenue CAGR, 15% EBIT margin target, 7.5% WACC and 14x terminal multiple. Balanced thesis with upside from innovation but risks from debt/growth. not investment advice.\"\n}", "parsedJson": { "as_of": "2026-04-08T20:00:03.000Z", "model": "AI Equity Research Model", "risks": [ "Sustained weakness in hospital spending", "Product liability and litigation risks", "Integration challenges from acquisitions", "Currency fluctuations in international markets", "Failure to meet innovation pipeline milestones" ], "ticker": "BDX", "currency": "USD", "scenarios": { "base": { "prob": 0.5, "notes": "Gradual recovery in growth and operating performance.", "target_price": 185 }, "bear": { "prob": 0.3, "notes": "Continued revenue weakness and no margin improvement.", "target_price": 140 }, "bull": { "prob": 0.2, "notes": "Accelerated growth from innovation and margin gains.", "target_price": 225 } }, "confidence": 0.62, "assumptions": { "wacc": 0.075, "revenue_cagr_3y": 0.05, "terminal_multiple": 14, "ebit_margin_target": 0.15 }, "key_drivers": [ { "driver": "Innovation and new product launches", "impact": "HIGH", "direction": "POS" }, { "driver": "Recovery in hospital capital expenditures", "impact": "HIGH", "direction": "POS" }, { "driver": "EBIT margin expansion initiatives", "impact": "MED", "direction": "POS" }, { "driver": "Debt reduction and deleveraging", "impact": "MED", "direction": "POS" }, { "driver": "Regulatory approvals and compliance", "impact": "MED", "direction": "NEG" }, { "driver": "Intense industry competition", "impact": "MED", "direction": "NEG" }, { "driver": "Global economic and healthcare spending", "impact": "HIGH", "direction": "POS" }, { "driver": "Supply chain cost inflation", "impact": "LOW", "direction": "NEG" } ], "method_notes": "DCF valuation anchored on 5% 3Y revenue CAGR, 15% EBIT margin target, 7.5% WACC and 14x terminal multiple. Balanced thesis with upside from innovation but risks from debt/growth. not investment advice.", "current_price": 157.09, "recommendation": "BUY", "thesis_bullets": [ "Leading medtech portfolio anchors resilient healthcare demand.", "Forward P/E of 12.5x signals compelling valuation entry.", "Innovation in key segments to drive mid-single digit growth.", "High debt burden elevates financial risk and interest costs.", "Recent negative revenue trends reflect cyclical hospital pressures." ], "target_price_6m": 165, "target_price_12m": 185 }, "errorsJson": { "attempts": [], "providerMeta": { "provider": "xai", "webSearch": { "used": false, "enabled": false, "sources": [], "maxToolCalls": 2 }, "responseId": "ab1b8c1c-b387-9c3f-bb81-20a486c4de92", "usedFallbackChatCompletions": false }, "sanityIssues": [] }, "latencyMs": 24972, "createdAt": "2026-04-09T05:19:47.605Z", "usage": { "inputTokens": 2705, "outputTokens": 4661, "costUsd": 0.07803 } } ] } }